Functional Medical Imaging Quantization in Prostate Cancer

NCT03376360 | Completed

• 1 other identifier: QUIP
• Study Type: observational
• Target: 61
• Locations: 1 country
• Sites: 1

Brief Summary

Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist. Several criteria guide this management in daily practice: PSA level; TNM stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the Gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum PSA, number of positive biopsies and percentage of cancer lesions by biopsy. Functional imaging by PET and MRI is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. In this context, it is the qualitative visual analysis that is mainly used. Quantitative image analysis could add new criteria to guide patient management. Consequently, the objective of this study were:

• Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer
• Comparison the quantitative parameters obtained by 18F-Choline PET / CT and both perfusion MRI and histological parameters.

Conditions

Prostate Cancer

Keywords

prostate cancer; Fcholine; positron emission tomography; MRI

Outcome Measures

Primary Outcomes (1)

• correlation between Gleason score and dynamic parameters on PET and MRI

  study the potential correlation between dynamic parameters on PET and MRI

  when anatomopathological report is available, an average of 3 months after the PET/CT

Secondary Outcomes (3)

• reconstructions on 18F-choline PET

  when all 18F-choline PET are performed, an average of 6 months

• best "fitting" on PET and MRI

  when all MRI are performed, an average of 6 months

• comparison between data (PSA, TNM stage, EFS and OS)

  01/05/2017

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with prostate cancer histologically proven included in Brest University Hospital between 01/07/2012 and 01/10/2015 and underwent F-choline PET/CT and pelvic MRI

You may qualify if:

• Patients with prostate cancer histologically proven included in Brest University Hospital between 01/07/2012 and 01/10/2015 and underwent F-choline PET/CT and pelvic MRI Patient consent

You may not qualify if:

• No lesion on dynamic acquisition on PET/CT and/or on pelvic MRI

Sponsors & Collaborators

• University Hospital, Brest: lead

Study Sites (1)

CHRU de Brest

Brest, 29609, France

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2017
• First Posted: December 18, 2017
• Study Start: October 1, 2015
• Primary Completion: May 1, 2017
• Study Completion: May 1, 2017
• Last Updated: August 15, 2018

Record last verified: 2017-11

Locations

FR (1)